Dr Mansukh Mandaviya reviews status of essential medicines with Pharma Companies

The pharma companies were asked to keep a close watch on the global supply chain scenario.;

Published On 2022-12-30 08:45 GMT | Update On 2022-12-30 08:45 GMT

New Delhi: Union Minister of Health & Family Welfare and Chemicals & Fertilizers, Dr. Mansukh Mandaviya reviewed the status, adequacy of COVID management drugs and production capacities with representatives of pharma companies through a VC, so that India is equipped to effectively handle any situation. This review meeting was taken in view of the spike in COVID-19 cases in some countries worldwide.

Through a presentation, the Union Minister was briefed regarding the evolving global scenario. Dr Mansukh Mandaviya appreciated and congratulated the pharma companies for their invaluable contribution during the COVID pandemic in the country.

"India's pharmaceutical industry is robust, resilient, and responsive. It is due to their strength that we could not only meet our down demand during the pandemic, but also be in a position to supply medicines to 150 countries." This was achieved without any fall in quality and no hike in the price of the medicines, he stressed.

The pharma companies were asked to keep a close watch on the global supply chain scenario. They were also asked to closely monitor production and availability of APIs as well as formulations of essential medicines for COVID management. They were asked to ensure adequate stocks and availability of all drugs including COVID drugs in the supply chain up to the retail level.

The pharma companies hailed the timely review meeting chaired by the Union Minister and assured their continued support. They expressed confidence that they will be able to manage the supply chain of COVID drugs.

Shri Rajesh Bhushan, Union Health Secretary, Ms. S Aparna, Secretary (Pharma), Shri Kamlesh Pant, Chairman, NPPA, Dr V G Somani, DCGI, and representatives from pharmaceutical companies were present during the review meeting.

Read also: CDSCO, State Drugs Control Administration begin joint inspection of drug manufacturing unit

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Dr Mansukh Mandaviya reviews status of essential medicines with Pharma Companies

The pharma companies were asked to keep a close watch on the global supply chain scenario.;

Similar News

Dr Reddy's Labs API Mirfield facility gets 7 USFDA observations

CDSCO Panel Rejects Theon Pharma's Proposal for Empagliflozin, Linagliptin, Metformin FDC

Virchow Biotech Gets CDSCO Panel Nod for Semaglutide BE, Phase III Trials

Industry needs to come forward, take advantage of funds available for MedTech Sector: DoP Joint Secretary

USFDA inspection: Aurobindo Pharma receives 8 observations for Unit-XII

USFDA issues 4 observations for Zydus Jarod injectable manufacturing plant

Lupin gets 2 USFDA observations for Aurangabad facility

Tamil Nadu Pharma Firms Under ED Lens for Suspected Financial Irregularities